Digital sequence information governance debates

Introduction

Digital Sequence Information (DSI) refers to digital representations of genetic information obtained from plants, animals, microorganisms and other biological resources. It includes DNA and RNA sequences and related genomic information stored, analysed and shared through electronic databases.

DSI has become increasingly important in biotechnology, agriculture, pharmaceutical research, synthetic biology and biodiversity conservation. Researchers can use digital genetic information to identify disease-resistant crops, develop medicines, study microorganisms and create genetically engineered products without necessarily transferring the original biological material.

However, the growing use of DSI has created major legal debates concerning ownership, access, intellectual property, benefit-sharing, national sovereignty and the rights of indigenous and local communities.

The central question is whether the commercial and scientific use of digital genetic information should generate benefit-sharing obligations similar to those applicable to the physical biological resources from which the information originated.

Legal and regulatory framework in India

1. Biological Diversity Act, 2002

The Biological Diversity Act, 2002, establishes India's framework for biodiversity conservation, sustainable utilisation and equitable benefit-sharing.

The National Biodiversity Authority (NBA), State Biodiversity Boards and Biodiversity Management Committees perform regulatory and institutional functions under the legislation.

The Biological Diversity (Amendment) Act, 2023 introduced changes to the regulatory framework, including provisions affecting access and benefit-sharing requirements.

An important legal debate concerns whether and under what circumstances the use of digital information derived from Indian biological resources should attract benefit-sharing obligations. The treatment of DSI must be assessed under the applicable statutory provisions and international developments rather than assuming that every digital sequence is automatically regulated like a physical biological sample.

2. Patents Act, 1970

The Patents Act governs patent protection for qualifying inventions developed using biological information.

Important provisions include:

Section 3(c): Excludes the mere discovery of a scientific principle or naturally occurring substance.

Section 3(j): Excludes plants and animals in whole or any part thereof, other than microorganisms, and essentially biological processes for production or propagation of plants and animals.

Section 6: Identifies persons entitled to apply for patents.

Therefore, identifying or digitising a naturally occurring DNA sequence does not automatically establish patent ownership. A qualifying technical invention must satisfy the statutory patentability requirements.

3. Protection of Plant Varieties and Farmers' Rights Act, 2001

This legislation recognises plant breeders' rights and farmers' interests in agricultural biodiversity.

Digital sequence information may support the identification and development of plant varieties. However, access to genetic information does not automatically eliminate farmers' statutory rights or create unrestricted ownership over traditional varieties.

4. Digital Personal Data Protection Act, 2023

The DPDP Act may apply when genomic information identifies or relates to an identifiable individual.

It is particularly relevant to human genetic databases, clinical genomic research and digital biological records. However, it should not be assumed that every sequence obtained from a plant or microorganism constitutes personal data.

Major governance debates concerning DSI

1. Ownership of digital sequence information

One major debate concerns whether DSI should be treated as freely accessible scientific information or as information subject to rights and restrictions associated with its biological origin.

Researchers generally support open scientific databases because unrestricted access encourages collaboration and innovation.

However, countries providing biological resources argue that commercial users should not obtain economic benefits without appropriate recognition or benefit-sharing.

The legal challenge is to distinguish between ownership of physical biological material, intellectual property in inventions and access to digital genetic information.

2. Access and benefit-sharing

The Convention on Biological Diversity and the Nagoya Protocol establish principles concerning access to genetic resources and fair and equitable sharing of benefits arising from their utilisation.

However, traditional access and benefit-sharing mechanisms were primarily developed around physical genetic resources.

DSI creates difficulties because researchers can download and analyse sequence information without physically obtaining the original biological material.

Consequently, international negotiations have focused on developing mechanisms that ensure fair benefit-sharing without unnecessarily restricting scientific research.

3. National sovereignty and international databases

Countries with rich biodiversity seek recognition of their sovereign rights over biological resources.

However, digital sequence databases operate internationally and allow researchers to access genetic information from multiple jurisdictions.

This creates questions about whether a country can impose restrictions on the use of information generated from its biological resources and how such restrictions can be enforced across borders.

4. Indigenous and local community rights

Traditional communities may have contributed to the identification, conservation and use of biological resources over generations.

DSI governance must therefore consider whether communities should receive recognition and benefits when their traditional resources contribute to commercial biotechnology products.

5. Intellectual property and scientific openness

Another important debate concerns the relationship between DSI and patent protection.

Open access to genetic information supports research, but unrestricted commercial exploitation may create concerns about unfair appropriation.

Patent systems must distinguish between naturally occurring genetic information and genuinely innovative technical inventions.

International legal framework

1. Convention on Biological Diversity, 1992

The Convention establishes principles concerning biodiversity conservation, sustainable use and fair benefit-sharing.

Article 15 addresses access to genetic resources and recognises national sovereignty over natural resources.

2. Nagoya Protocol, 2010

The Nagoya Protocol establishes a framework for access to genetic resources and equitable sharing of benefits arising from their utilisation.

Its relationship with DSI has been a major subject of international negotiations.

3. Kunming-Montreal Global Biodiversity Framework, 2022

The framework recognises the importance of biodiversity conservation and includes Target 13 concerning fair and equitable benefit-sharing from genetic resources and associated traditional knowledge.

4. COP16 Cali Fund decision, 2024

At the sixteenth Conference of the Parties to the Convention on Biological Diversity, governments adopted arrangements for a multilateral mechanism for benefit-sharing from DSI, including the establishment of the Cali Fund.

The mechanism encourages companies in specified sectors that commercially benefit from DSI to contribute to the fund, subject to the applicable international arrangements.

The fund is intended to support biodiversity conservation and benefit-sharing, including benefits for indigenous peoples and local communities.

5. International Treaty on Plant Genetic Resources for Food and Agriculture, 2001

This Treaty establishes a multilateral system for facilitating access to specified plant genetic resources for food and agriculture and sharing benefits arising from their utilisation.

Its relationship with DSI and other international access and benefit-sharing mechanisms remains an important governance issue.

Important case laws

Direct Indian judicial decisions specifically addressing digital sequence information governance are limited. However, several decisions establish relevant principles concerning biological resources, traditional knowledge, intellectual property and benefit-sharing.

1. Divya Pharmacy v. Union of India (2018) SCC OnLine Utt 1035

The Uttarakhand High Court examined benefit-sharing obligations under the Biological Diversity Act, 2002.

The judgment recognised the importance of equitable benefit-sharing when biological resources are commercially utilised.

It is relevant to DSI governance because digital genetic information may originate from biological resources whose utilisation raises questions of national and community interests. However, the decision did not directly determine the legal status of DSI.

2. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381

The Supreme Court considered disputes concerning genetically modified cotton technology and the interaction between patent protection and plant variety legislation.

The decision is relevant to DSI governance because genetic information is increasingly used to develop agricultural biotechnology inventions. It demonstrates the importance of examining the precise statutory basis of intellectual property protection.

3. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court interpreted Section 3(d) of the Patents Act and explained the importance of preventing patent protection for certain modifications that fail to satisfy statutory requirements.

Its broader principles are relevant to genetic information because naturally occurring biological discoveries cannot automatically receive patent protection merely through identification or commercial application.

4. Council for Scientific and Industrial Research v. University of Mississippi (Turmeric Patent Dispute, US Patent No. 5,401,504)

The United States Patent and Trademark Office revoked a patent concerning the use of turmeric for wound healing after CSIR produced evidence of prior traditional knowledge and publications.

The dispute demonstrates how documented traditional knowledge can prevent inappropriate patent claims over biological uses already known to communities.

It is relevant to DSI governance because digital sequence databases can help document existing biological knowledge and establish prior art.

5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) 569 U.S. 576

The United States Supreme Court held that naturally occurring DNA segments are not patentable merely because they have been isolated.

This decision is important for DSI governance because the digital representation of a naturally occurring DNA sequence does not automatically create a patentable invention.

These cases provide analogous legal principles rather than direct judicial rules governing international DSI benefit-sharing.

Regulatory challenges and future developments

DSI governance faces several continuing challenges.

Cross-border enforcement: Digital sequence information can be accessed internationally without transferring physical biological materials.

Benefit-sharing mechanisms: Regulators must develop workable systems that distribute benefits fairly without obstructing research.

Database transparency: Scientific databases need clear policies concerning access, attribution and permitted uses.

Traditional knowledge protection: Indigenous and local communities require meaningful participation in decisions involving their biological resources.

Patent examination: Patent offices must distinguish natural genetic discoveries from qualifying technical inventions.

Commercial accountability: Biotechnology companies may need transparent procedures for identifying DSI-related commercial benefits and meeting applicable contribution obligations.

India must also coordinate biodiversity legislation, agricultural intellectual property rules and international benefit-sharing arrangements to create a consistent regulatory approach.

Conclusion

Digital Sequence Information governance is an emerging area of international biotechnology law involving biodiversity conservation, intellectual property, national sovereignty and equitable benefit-sharing. India's Biological Diversity Act, 2002, Patents Act, 1970 and Protection of Plant Varieties and Farmers' Rights Act, 2001 provide important domestic legal foundations. International developments under the Convention on Biological Diversity, Nagoya Protocol and COP16 Cali Fund arrangements are shaping the future of DSI regulation. Judicial decisions such as Divya Pharmacy, Monsanto Technology v. Nuziveedu Seeds and Myriad Genetics offer relevant principles concerning biological resources and intellectual property. However, direct judicial decisions on DSI governance remain limited. A balanced framework must preserve scientific openness while ensuring fair benefits for biodiversity-rich countries and communities contributing to genetic resource conservation.